Codexis, Inc. (CDXS) Insider Sells $259,920.05 in Stock

Codexis, Inc. (NASDAQ:CDXS) insider John J. Nicols sold 22,465 shares of the company’s stock in a transaction dated Friday, March 23rd. The shares were sold at an average price of $11.57, for a total transaction of $259,920.05. Following the completion of the transaction, the insider now directly owns 1,078,990 shares in the company, valued at approximately $12,483,914.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Codexis, Inc. (CDXS) opened at $11.00 on Monday. Codexis, Inc. has a 1 year low of $3.95 and a 1 year high of $13.60. The company has a current ratio of 1.80, a quick ratio of 1.76 and a debt-to-equity ratio of 0.02.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.03). The business had revenue of $21.70 million for the quarter, compared to analyst estimates of $22.97 million. Codexis had a negative return on equity of 103.42% and a negative net margin of 45.97%. The firm’s revenue for the quarter was up 117.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.07) EPS. research analysts expect that Codexis, Inc. will post -0.25 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Thompson Davis & CO. Inc. lifted its position in shares of Codexis by 1,753.5% during the fourth quarter. Thompson Davis & CO. Inc. now owns 18,535 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 17,535 shares in the last quarter. Burney Co. acquired a new stake in shares of Codexis during the fourth quarter worth about $167,000. MetLife Investment Advisors LLC acquired a new stake in shares of Codexis during the fourth quarter worth about $179,000. The Manufacturers Life Insurance Company lifted its position in shares of Codexis by 30.5% during the second quarter. The Manufacturers Life Insurance Company now owns 35,264 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 8,244 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Codexis during the fourth quarter worth about $202,000. 70.84% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on CDXS shares. BidaskClub raised shares of Codexis from a “hold” rating to a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Finally, HC Wainwright set a $12.00 price target on shares of Codexis and gave the stock a “buy” rating in a research report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $9.75.

ILLEGAL ACTIVITY WARNING: “Codexis, Inc. (CDXS) Insider Sells $259,920.05 in Stock” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3301578/codexis-inc-cdxs-insider-sells-259920-05-in-stock.html.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.